Key Takeaways
- • Bank of America's broker-dealer units have reached a tentative settlement to resolve a hedge fund's long-running lawsuit alleging stock manipulation in a former Canadian pharmaceutical company, according to a May 27, 2026 filing in New York federal court.
- • The settlement ends litigation over alleged "spoofing" tactics—a form of market manipulation involving placement and cancellation of orders to create false impressions of market demand—allegedly used between January 2020 and August 2024.
- • Quantum BioPharma Ltd., the Toronto-based biopharmaceutical company behind the original claim, had secured a significant court victory earlier in the litigation, with a New York federal judge ruling the company could pursue most of its lawsuit against multiple Canadian banking institutions and their brokerage arms.
- • The original complaint named CIBC World Markets Inc. and the Royal Bank of Canada's brokerage operations among defendants accused of facilitating or permitting spoofing activity that allegedly harmed the company's stock valuation.
Summary
Bank of America's broker-dealer units have reached a tentative settlement to exit a protracted legal battle initiated by Quantum BioPharma Ltd., a Toronto-based biopharmaceutical company, over allegations of stock price manipulation through spoofing tactics. The settlement was disclosed in a filing with the U.S. District Court for the Southern District of New York on May 27, 2026, marking a significant development in what has been a multi-year litigation effort.
The lawsuit centered on alleged market manipulation spanning from January 1, 2020, through August 15, 2024, during which the defendants and their customers allegedly employed spoofing techniques to artificially influence the trading activity and price of Quantum BioPharma's securities. Spoofing—the practice of placing large orders with the intent to cancel them before execution—is designed to create false impressions of market depth or demand and is prohibited under securities laws. The original complaint identified CIBC World Markets Inc. and the Royal Bank of Canada's brokerage operations as key defendants, alongside Bank of America's broker-dealer units.
Prior to this settlement announcement, Quantum BioPharma had achieved a notable legal milestone when a New York federal judge ruled that the company could proceed with the majority of its claims against the named defendants, rejecting joint motions to dismiss the underlying complaint. This judicial determination reinforced the viability of the plaintiff's allegations and likely provided leverage in settlement negotiations with BofA's units.
The tentative nature of the settlement, as described in the court filing, suggests final approval remains pending, though the agreement represents a material reduction in litigation exposure for the bank's broker-dealer operations. Settlement of this claim eliminates ongoing defense costs and the uncertainty of jury trial outcomes for one of the named parties, while potentially signaling momentum toward broader resolution of similar claims against other defendants in the action.
The lawsuit centered on alleged market manipulation spanning from January 1, 2020, through August 15, 2024, during which the defendants and their customers allegedly employed spoofing techniques to artificially influence the trading activity and price of Quantum BioPharma's securities. Spoofing—the practice of placing large orders with the intent to cancel them before execution—is designed to create false impressions of market depth or demand and is prohibited under securities laws. The original complaint identified CIBC World Markets Inc. and the Royal Bank of Canada's brokerage operations as key defendants, alongside Bank of America's broker-dealer units.
Prior to this settlement announcement, Quantum BioPharma had achieved a notable legal milestone when a New York federal judge ruled that the company could proceed with the majority of its claims against the named defendants, rejecting joint motions to dismiss the underlying complaint. This judicial determination reinforced the viability of the plaintiff's allegations and likely provided leverage in settlement negotiations with BofA's units.
The tentative nature of the settlement, as described in the court filing, suggests final approval remains pending, though the agreement represents a material reduction in litigation exposure for the bank's broker-dealer operations. Settlement of this claim eliminates ongoing defense costs and the uncertainty of jury trial outcomes for one of the named parties, while potentially signaling momentum toward broader resolution of similar claims against other defendants in the action.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.